Premature Ovarian Insufficiency: New Perspectives On Genetic Cause And Phenotypic Spectrum

Endocrine Reviews

Volumn 37, Issue 6, 2016, Pages 609-635

  Tucker, Elena J ^a,b   Grover, Sonia R ^a,b   Bachelot, Anne ^c,d   Touraine, Philippe ^c,d   Sinclair, Andrew H ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GONADOTROPIN;

CRYOPRESERVATION; FEMALE INFERTILITY; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; IMMUNOREGULATION; NONHUMAN; OOCYTE DEVELOPMENT; OVARY DEVELOPMENT; OVARY FOLLICLE DEVELOPMENT; OVULATION; PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; PREMATURE OVARIAN FAILURE; PRIMARY AMENORRHEA; PRIORITY JOURNAL; REVIEW; SECONDARY AMENORRHEA; ANIMAL; FEMALE; GENETICS;

ANIMALS; FEMALE; HUMANS; PRIMARY OVARIAN INSUFFICIENCY;

EID: 85009821134     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2016-1047     Document Type: Review

References (253)

1. Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric. 2016;19(1):27-36.
2. Eastell R. Management of osteoporosis due to ovarian failure. Med Pediatr Oncol. 2003;41(3):222-227.
3. Goswami D, Conway GS. Premature ovarian failure. Horm Res. 2007;68(4):196-202.
4. Qin Y, Jiao X, Simpson JL, Chen ZJ. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update. 2015;21(6):787-808.
5. Tucker EJ, Sinclair AH. Mammalian sex determination. Encyclopedia of Life Sciences. Chichester, UK: John Wiley & Sons, Ltd; 2013.
6. Eggers S, Ohnesorg T, Sinclair A. Genetic regulation of mammalian gonad development. Nat Rev Endocrinol. 2014;10(11):673-683.
7. Chassot AA, Gillot I, Chaboissier MC. R-spondin1, WNT4, and theCTNNB1signaling pathway: strict control over ovarian differentiation. Reproduction. 2014;148(6): R97-R110.
8. Lin YT, Capel B. Cell fate commitment during mammalian sex determination. Curr Opin Genet Dev. 2015;32:144-152.
9. Gosden RG. Oocyte development and loss. Semin Reprod Med. 2013;31(6):393-398.
10. Pepling ME. From primordial germ cell to primordial follicle: mammalian female germ cell development. Genesis. 2006;44(12):622-632.
11. Pereda J, Zorn T, Soto-Suazo M. Migration of human and mouse primordial germ cells and colonization of the dedoi veloping ovary: an ultrastructural and cytochemical study. Microsc Res Tech. 2006;69(6):386-395.
12. Mamsen LS, Brchner CB, Byskov AG, Mllgard K. The migration and loss of human primordial germ stem cells from the hind gut epithelium towards the gonadal ridge. Int J Dev Biol. 2012;56(10-12):771-778.
13. Kerr JB, Myers M, Anderson RA. The dynamics of the primordial follicle reserve. Reproduction. 2013;146(6): R205-R215.
14. Forabosco A, Sforza C. Establishment of ovarian reserve: a quantitative morphometric study of the developing human ovary. Fertil Steril. 2007;88(3):675-683.
15. Mamsen LS, Lutterodt MC, Andersen EW, Byskov AG, Andersen CY. Germ cell numbers in human embryonic and fetal gonads during the first two trimesters of pregnancy: analysis of six published studies. Hum Reprod. 2011; 26(8):2140-2145.
16. Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev. 1996; 17(2):121-155.
17. Kaipia A, Hsueh AJ. Regulation of ovarian follicle atresia. Annu Rev Physiol. 1997;59:349-363.
18. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1): e8772.
19. Gervsio CG, BernuciMP, Silva-de-SMF, Rosa-E-Silva AC. The role of androgen hormones in early follicular development. ISRN Obstet Gynecol. 2014;2014:818010.
20. Skinner MK. Regulation of primordial follicle assembly and development. Hum Reprod Update. 2005;11(5):461-471.
21. Savoy-Moore RT, Swartz KH. Several GnRH stimulation frequencies differentially release FSH and LH from isolated, perfused rat anterior pituitary cells. Adv Exp Med Biol. 1987;219:641-645.
22. Wildt L, Husler A, Marshall G, et al. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology. 1981;109(2):376-385.
23. Gougeon A. Human ovarian follicular development: from activation of resting follicles to preovulatory maturation. Ann Endocrinol (Paris). 2010;71(3):132-143.
24. Filicori M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril. 1999;71(3): 405-414.
25. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod. 19(2)94;9:188-191.
26. Treloar AE. Menstrual cyclicity and the pre-menopause. Maturitas. 1981;3(3-4):249-264.
27. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 2008;61(1-2):4-16.
28. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604-606.
29. Fabre S, Pierre A, Pisselet C, et al. The Booroola mutation in sheep is associated with an alteration of the bone morphogenetic protein receptor-IB functionality. J Endocrinol. 2003;177(3):435-444.
30. Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. 2011; 96(12):3864-3872.
31. Bidet M, Bachelot A, Touraine P. Premature ovarian failure: predictability of intermittent ovarian function and response to ovulation induction agents. Curr Opin Obstet Gynecol. 2008;20(4):416-420.
32. Bachelot A, Nicolas C, Bidet M, et al. Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency [published online ahead of print May 14, 2016.]. Clin Endocrinol (Oxf). doi: 10.1111/cen.13105.
33. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril. 2005;83(5):1327-1332.
34. Webber L, DaviesM, Anderson R, et al.ESHREGuideline: Management of Women With Premature Ovarian Insufficiency. Grimbergen, Belgium: European Society of Human Reproduction and Embryology; 2015.
35. Albright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature: report of 11 cases with a digression on hormonal control of axillary and pubic hair.AmJMedSci. 1942;204:625-648.
36. Cooper AR, Baker VL, Sterling EW, Ryan ME, Woodruff TK, Nelson LM. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril. 2011;95(6): 1890-1897.
37. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606-614.
38. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009; 30(5):465-493.
39. Gordon CM, Kanaoka T, Nelson LM. Update on primary ovarian insufficiency in adolescents. Curr Opin Pediatr. 2015;27(4):511-519.
40. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet J Rare Dis. 2006;1:9.
41. Massin N, Gougeon A, Meduri G, et al. Significance of ovarian histology in the management of patients presenting a premature ovarian failure. Hum Reprod. 2004;19(11): 2555-2560.
42. Mduri G, Massin N, Guibourdenche J, et al. Serum anti-Mllerian hormone expression in women with premature ovarian failure. Hum Reprod. 2007;22(1):117-123.
43. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Antimullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478-3483.
44. van Disseldorp J, Faddy MJ, Themmen AP, et al. Relationship of serum antimllerian hormone concentration to age at menopause. J Clin Endocrinol Metab. 2008;93(6):2129-2134.
45. Jacquesson L, Bachelot A, Touraine P. Anti-Müllerian Hormone and Premature Ovarian Insufficiency. In: Seifer DB, Tal R, eds. Anti-Müllerian Hormone: Biology, Role in Ovarian Function and Clinical Significance. 1st ed. New York, NY: Nova Science Publishers, Inc; 2016:197-208.
46. Bachelot A, Rouxel A, Massin N, et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol. 2009;161(1): 179-187.
47. Vegetti W, Grazia Tibiletti M, Testa G, et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. Hum Reprod. 1998;13(7):1796-1800.
48. Torgerson DJ, ThomasRE, ReidDM.Mothers and daughters menopausal ages: is there a link? Eur J Obstet Gynecol Reprod Biol. 1997;74(1):63-66.
49. Lin L, Achermann JC. Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development. Sex Dev. 2008;2(4-5):200-209.
50. Loureno D, Brauner R, Lin L, et al. Mutations in NR5A1 associated with ovarian insufficiency.NEngl J Med. 2009; 360(12):1200-1210.
51. Voican A, Bachelot A, Bouligand J, et al. NR5A1 (SF-1) mutations are not a major cause of primary ovarian insufficiency. J Clin Endocrinol Metab. 2013;98(5):E1017-E1021.
52. Janse F, de With LM, Duran KJ, et al. Limited contribution of NR5A1 (SF-1) mutations in women with primary ovarian insufficiency (POI). Fertil Steril. 2012;97(1):141-146.e2.
53. Philibert P, Paris F, Lakhal B, et al. NR5A1 (SF-1) gene variants in a group of 26 young women with XX primary ovarian insufficiency. Fertil Steril. 2013;99(2):484-489.
54. Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet. 2001; 27(2):159-166.
55. Fraser IS, Shearman RP, Smith A, Russell P. An association among blepharophimosis, resistant ovary syndrome, and true premature menopause. Fertil Steril. 1988;50(5):747-751.
56. Nicolino M, Bost M, David M, Chaussain JL. Familial blepharophimosis: an uncommon marker of ovarian dysgenesis. J Pediatr Endocrinol Metab. 1995;8(2):127-133.
57. Uhlenhaut NH, Jakob S, Anlag K, et al. Somatic sex reprogramming of adult ovaries to testes byFOXL2ablation. Cell. 2009;139(6):1130-1142.
58. Cocquet J, De Baere E, Gareil M, et al. Structure, evolution and expression of the FOXL2 transcription unit. Cytogenet Genome Res. 2003;101(3-4):206-211.
59. Cocquet J, Pailhoux E, Jaubert F, et al. Evolution and expression of FOXL2. J Med Genet. 2002;39(12):916-921.
60. Pisarska MD, Bae J, Klein C, Hsueh AJ. Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. Endocrinology. 2004;145(7):3424-3433.
61. Schmidt D, Ovitt CE, Anlag K, et al. The murine wingedhelix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development. 2004;131(4):933-942.
62. Uda M, Ottolenghi C, Crisponi L, et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. Hum Mol Genet. 2004;13(11):1171-1181.
63. Mduri G, Bachelot A, Duflos C, et al. FOXL2 mutations lead to different ovarian phenotypes in BPES patients: Case Report. Hum Reprod. 2010;25(1):235-243.
64. Demirhan O, Trkmen S, Schwabe GC, et al.Ahomozygous BMPR1Bmutation causes anewsubtype of acromesomelic chondrodysplasia with genital anomalies. J Med Genet. 2005;42(4):314-317.
65. McPherson E, Turner L, Zador I, Reynolds K, Macgregor D, Giampietro PF. Ovarian failure and dilated cardiomyopathy due to a novel lamin mutation. Am J Med Genet A. 2009;149A(4):567-572.
66. Caburet S, Arboleda VA, Llano E, et al. Mutant cohesin in premature ovarian failure. N Engl J Med. 2014;370(10): 943-949.
67. Faridi R, RehmanAU, Morell RJ, et al. Mutations ofSGO2 and CLDN14 collectively cause coincidental Perrault syndrome [published online ahead of print September 15, 2016]. Clin Genet. doi: 10.1111/cge.12867.
68. Llano E, Gmez R, Gutirrez-Caballero C, et al. Shugoshin-2 is essential for the completion of meiosis but not for mitotic cell division in mice. Genes Dev. 2008;22(17):2400-2413.
69. Lacombe A, Lee H, Zahed L, et al. Disruption of POF1B binding to nonmuscle actin filaments is associated with premature ovarian failure. Am J Hum Genet. 2006;79(1): 113-119.
70. Bolcun-Filas E, Hall E, Speed R, et al. Mutation of the mouse Syce1 gene disrupts synapsis and suggests a link between synaptonemal complex structural components and DNA repair. PLoS Genet. 2009;5(2):e1000393.
71. de Vries L, Behar DM, Smirin-Yosef P, Lagovsky I, Tzur S, Basel-Vanagaite L. Exome sequencing reveals SYCE1 mutation associated with autosomal recessive primary ovarian insufficiency. J Clin Endocrinol Metab. 2014;99(10): E2129-E2132.
72. de Vries FA, de Boer E, van den Bosch M, et al. Mouse Sycp1 functions in synaptonemal complex assembly, meiotic recombination, and XY body formation. Genes Dev. 2005;19(11):1376-1389.
73. Bolcun-Filas E, Costa Y, Speed R, et al. SYCE2 is required for synaptonemal complex assembly, double strand break repair, and homologous recombination. J Cell Biol. 2007; 176(6):741-747.
74. Hamer G, Wang H, Bolcun-Filas E, Cooke HJ, Benavente R, H C. Progression of meiotic recombination requires structural maturation of the central element of the synaptonemal complex. J Cell Sci. 2008;121:2445-2451.
75. Wang J, Zhang W, Jiang H, Wu BL, Primary Ovarian Insufficiency Collaboration. Mutations inHFM1in recessive primary ovarian insufficiency. N Engl J Med. 2014; 370(10):972-974.
76. Zangen D, Kaufman Y, Zeligson S, et al. XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription. Am J Hum Genet. 2011;89(4):572-579.
77. Weinberg-Shukron A, Renbaum P, Kalifa R, et al. A mutation in the nucleoporin-107 gene causesXXgonadal dysgenesis. J Clin Invest. 2015;125(11):4295-4304.
78. Knockenhauer KE, Schwartz TU. The nuclear pore complex as a flexible and dynamic gate. Cell. 2016;164(6): 1162-1171.
79. Senger S, Csokmay J, Akbar T, et al. The nucleoporin Seh1 forms a complex with Mio and serves an essential tissuespecific function in Drosophila oogenesis. Development. 2011;138(10):2133-2142.
80. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749-1753.
81. Miller ME, Chatten J. Ovarian changes in ataxia telangiectasia. Acta Paediatr Scand. 1967;56(5):559-561.
82. Arora H, Chacon AH, Choudhary S, et al. Bloom syndrome. Int J Dermatol. 2014;53(7):798-802.
83. Rossi ML, Ghosh AK, Bohr VA. Roles of Werner syndrome protein in protection of genome integrity.DNARepair (Amst). 2010;9(3):331-344.
84. Siitonen HA, Sotkasiira J, Biervliet M, et al. The mutation spectrum in RECQL4 diseases. Eur J Hum Genet. 2009; 17(2):151-158.
85. Chrzanowska KH, Gregorek H, Dembowska-Bagiska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis. 2012;7:13.
86. Chrzanowska KH, Szarras-Czapnik M, Gajdulewicz M, et al. High prevalence of primary ovarian insufficiency in girls and young women with Nijmegen breakage syndrome: evidence from a longitudinal study. J Clin Endocrinol Metab. 2010;95(7):3133-3140.
87. Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab. 2007;92(7):2624-2631.
88. AlAsiri S, Basit S, Wood-Trageser MA, et al. Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. J Clin Invest. 2015; 125(1):258-262.
89. Wood-Trageser MA, Gurbuz F, Yatsenko SA, et al. MCM9 mutations are associated with ovarian failure, short stature, and chromosomal instability. Am J Hum Genet. 2014;95(6):754-762.
90. Fauchereau F, Shalev S, Chervinsky E, et al. A non-sense MCM9 mutation in a familial case of primary ovarian insufficiency. Clin Genet. 2016;89(5):603-607.
91. Goldberg Y, Halpern N, Hubert A, et al. Mutated MCM9 is associated with predisposition to hereditary mixed polyposis and colorectal cancer in addition to primary ovarian failure. Cancer Genet. 2015;208(12):621-624.
92. Qin Y, Guo T, Li G, et al. CSB-PGBD3 mutations cause premature ovarian failure. PLoS Genet. 2015;11(7): e1005419.
93. Stolk L, Perry JR, Chasman DI, et al. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet. 2012; 44(3):260-268.
94. Krakauer DC, Mira A. Mitochondria and germ-cell death. Nature. 1999;400(6740):125-126.
95. Morita Y, Tilly JL. Oocyte apoptosis: like sand through an hourglass. Dev Biol. 1999;213(1):1-17.
96. De Felici M, Klinger FG, Farini D, Scaldaferri ML, Iona S, Lobascio M. Establishment of oocyte population in the fetal ovary: primordial germ cell proliferation and oocyte programmed cell death. Reprod Biomed Online. 2005; 10(2):182-191.
97. Santos MG, Machado AZ, Martins CN, et al. Homozygous inactivating mutation in NANOS3 in two sisters with primary ovarian insufficiency. Biomed Res Int. 2014; 2014:787465.
98. WuX, WangB, Dong Z, et al.ANANOS3mutation linked to protein degradation causes premature ovarian insufficiency. Cell Death Dis. 2013;4:e825.
99. MansouriMR, Schuster J, Badhai J, et al. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. Hum Mol Genet. 2008;17(23):3776-3783.
100. Ratts VS, Flaws JA, Kolp R, Sorenson CM, Tilly JL. Ablation of bcl-2 gene expression decreases the numbers of oocytes and primordial follicles established in the postnatal female mouse gonad. Endocrinology. 1995;136(8): 3665-3668.
101. Fogli A, Rodriguez D, Eymard-Pierre E, et al. Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet. 2003;72(6):1544-1550.
102. Coppieters F, Ascari G, Dannhausen K, et al. Isolated and syndromic retinal dystrophy caused by biallelic mutations in RCBTB1, a gene implicated in ubiquitination. Am J Hum Genet. 2016;99(2):470-480.
103. Kasippillai T, MacArthur DG, Kirby A, et al. Mutations in eIF4ENIF1 are associated with primary ovarian insufficiency. J Clin Endocrinol Metab. 2013;98(9):E1534-E1539.
104. Pfender S, Kuznetsov V, Pasternak M, Tischer T, Santhanam B, Schuh M. Live imaging RNAi screen reveals genes essential for meiosis in mammalian oocytes. Nature. 2015; 524(7564):239-242.
105. Persani L, Rossetti R, Di Pasquale E, Cacciatore C, Fabre S. The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. Hum Reprod Update. 20(6)14;20:869-883.
106. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet. 2004;75(1):106-111.
107. Hanrahan JP, Gregan SM, Mulsant P, et al. Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovis aries). Biol Reprod. 2004;70(4):900-909.
108. Shimasaki S, Moore RK, Erickson GF, Otsuka F. The role of bone morphogenetic proteins in ovarian function. Reprod Suppl. 2003;61:323-337.
109. Kosaki K, Sato S, Hasegawa T, Matsuo N, Suzuki T, Ogata T. Premature ovarian failure in a female with proximal symphalangism and Noggin mutation. Fertil Steril. 2004; 81(4):1137-1139.
110. Kadi N, Tahiri L, MazianeM, Mernissi FZ, Harzy T. Proximal symphalangism and premature ovarian failure. Joint Bone Spine. 2012;79(1):83-84.
111. Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature. 1996; 383(6600):531-535.
112. Dixit H, Rao LK, Padmalatha V, et al. Mutational screening of the coding region of growth differentiation factor 9 gene in Indian women with ovarian failure. Menopause. 2005;12(6):749-754.
113. Kovanci E, Rohozinski J, Simpson JL, Heard MJ, Bishop CE, Carson SA. Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril. 2007;87(1):143-146.
114. Zhao H, Qin Y, Kovanci E, Simpson JL, Chen ZJ, Rajkovic A. Analyses ofGDF9mutation in 100 Chinesewomenwith premature ovarian failure. Fertil Steril. 2007;88(5):1474-1476.
115. Suzumori N, Yan C, Matzuk MM, Rajkovic A. Nobox is a homeobox-encoding gene preferentially expressed in primordial and growing oocytes. Mech Dev. 2002;111(1-2): 137-141.
116. Rajkovic A, Pangas SA, Ballow D, Suzumori N, Matzuk MM. NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. Science. 2004; 305(5687):1157-1159.
117. Qin Y, Choi Y, Zhao H, Simpson JL, Chen ZJ, Rajkovic A. NOBOX homeobox mutation causes premature ovarian failure. Am J Hum Genet. 2007;81(3):576-581.
118. Bouilly J, Bachelot A, Broutin I, Touraine P, Binart N. Novel NOBOX loss-of-function mutations account for 6.2% of cases in a large primary ovarian insufficiency cohort. Hum Mutat. 2011;32(10):1108-1113.
119. Bouilly J, Roucher-Boulez F, Gompel A, Bry-Gauillard H, Azibi K, et al.NewNOBOXmutations identified in a large cohort of women with primary ovarian insufficiency decrease KIT-L expression. J Clin Endocrinol Metab. 2015; 100(3):994-1001.
120. Bouali N, Francou B, Bouligand J, et al. NOBOX is a strong autosomal candidate gene in Tunisian patients with primary ovarian insufficiency. Clin Genet. 2016;89(5): 608-613.
121. Bayram Y, Gulsuner S, Guran T, et al. Homozygous lossof-function mutations in SOHLH1 in patients with nonsyndromic hypergonadotropic hypogonadism. J Clin Endocrinol Metab. 2015;100(5):E808-E814.
122. Pangas SA, Choi Y, Ballow DJ, et al. Oogenesis requires germ cell-specific transcriptional regulators Sohlh1 and Lhx8. Proc Natl Acad Sci USA. 2006;103(21):8090-8095.
123. Matthews CH, Borgato S, Beck-Peccoz P, et al. Primary amenorrhoea and infertility due to a mutation in theβ-subunit of follicle-stimulating hormone. Nat Genet. 1993; 5(1):83-86.
124. Layman LC, Lee EJ, Peak DB, et al. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone β-subunit gene. N Engl J Med. 1997; 337(9):607-611.
125. Aittomki K, Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell. 1995;82(6): 959-968.
126. Allen LA, Achermann JC, Pakarinen P, et al. A novel loss of function mutation in exon 10 of the FSH receptor gene causing hypergonadotrophic hypogonadism: clinical and molecular characteristics. Hum Reprod. 2003;18(2):251-256.
127. Meduri G, Touraine P, Beau I, et al. Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. J Clin Endocrinol Metab. 2003;88(8):3491-3498.
128. Touraine P, Beau I, Gougeon A, et al. New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. Mol Endocrinol. 1999;13(11):1844-1854.
129. Doherty E, Pakarinen P, Tiitinen A, et al.Anovel mutation in the FSH receptor inhibiting signal transduction and causing primary ovarian failure. J Clin Endocrinol Metab. 2002;87(3):1151-1155.
130. Beau I, Touraine P, Meduri G, et al. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. J Clin Invest. 1998;102(7): 1352-1359.
131. Vaskivuo TE, Aittomki K, Anttonen M, et al. Effects of follicle-stimulating hormone (FSH) and human chorionic gonadotropin in individuals with an inactivating mutation of the FSH receptor. Fertil Steril. 2002;78(1):108-113.
132. Messinis IE, Messini CI, Dafopoulos K. Novel aspects of the endocrinology of the menstrual cycle. Reprod Biomed Online. 2014;28(6):714-722.
133. Bose HS, Pescovitz OH, Miller WL. Spontaneous feminization in a 46, XX female patient with congenital lipoid adrenal hyperplasia due to a homozygous frameshift mutation in the steroidogenic acute regulatory protein. J Clin Endocrinol Metab. 1997;82(5):1511-1515.
134. Miura K, Yasuda K, Yanase T, et al. Mutation of cytochrome P-45017 β gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. J Clin Endocrinol Metab. 1996; 81(10):3797-3801.
135. Simsek E, Ozdemir I, Lin L, Achermann JC. Isolated 17, 20-lyase (desmolase) deficiency in a 46, XX female presenting with delayed puberty. Fertil Steril. 2005;83(5):1548-1551.
136. Conte FA, GrumbachMM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab. 1994;78(6): 1287-1292.
137. Ito Y, Fisher CR, Conte FA, GrumbachMM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci USA. 1993;90(24):11673-11677.
138. Kumar M, Pathak D, Venkatesh S, Kriplani A, Ammini AC, Dada R. Chromosomal abnormalities & oxidative stress in women with premature ovarian failure (POF). Indian J Med Res. 2012;135:92-97.
139. Tokmak A, Ym G, Sarkaya E, et al. Increased oxidative stress markers may be a promising indicator of risk for primary ovarian insufficiency: a cross-sectional case control study. Rev Bras Ginecol Obstet. 2015;37(9):411-416.
140. Venkatesh S, Kumar M, Sharma A, et al. Oxidative stress and ATPase6 mutation is associated with primary ovarian insufficiency. Arch Gynecol Obstet. 2010;282(3):313-318.
141. Legros F, Malka F, Frachon P, Lombs A, Rojo M. Organization and dynamics of human mitochondrial DNA. J Cell Sci. 2004;117(Pt 13):2653-2662.
142. Satoh M, Kuroiwa T. Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell. Exp Cell Res. 1991;196(1):137-140.
143. Pik L, Taylor KD. Amounts of mitochondrial DNA and abundance of some mitochondrial gene transcripts in early mouse embryos. Dev Biol. 1987;123(2):364-374.
144. Shoubridge EA, Wai T. Mitochondrial DNA and the Mammalian Oocyte. Curr Top Dev Biol. 2007;77:87-111.
145. Bonomi M, Somigliana E, Cacciatore C, et al. Blood cell mitochondrialDNAcontent and premature ovarian aging. PLoS One. 2012;7(8):e42423.
146. Pagnamenta AT, Taanman JW, Wilson CJ, et al. Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase γ. Hum Reprod. 2006;21(10):2467-2473.
147. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymeraseγ mutations: clinical and molecular genetic study. Lancet. 2004;364(9437):875-882.
148. Morino H, Pierce SB, Matsuda Y, et al. Mutations in Twinkle primase-helicase cause Perrault syndrome with neurologic features. Neurology. 2014;83(22):2054-2061.
149. Pierce SB, Gersak K, Michaelson-Cohen R, et al. Mutations in LARS2, encoding mitochondrial leucyl-tRNA synthetase, lead to premature ovarian failure and hearing loss in Perrault syndrome.AmJ Hum Genet. 2013;92(4):614-620.
150. Pierce SB, Chisholm KM, Lynch ED, et al. Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome. Proc Natl Acad Sci USA. 2011;108(16): 6543-6548.
151. Dallabona C, Diodato D, Kevelam SH, et al. Novel (ovario) leukodystrophy related to AARS2 mutations. Neurology. 2014;82(23):2063-2071.
152. Jenkinson EM, Rehman AU, Walsh T, et al. Perrault syndrome is caused by recessive mutations in CLPP, encoding a mitochondrial ATP-dependent chambered protease. Am J Hum Genet. 2013;92(4):605-613.
153. Pierce SB, Walsh T, Chisholm KM, et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome. Am J Hum Genet. 2010;87(2):282-288.
154. Banerjee S, Chakraborty P, Saha P, Bandyopadhyay SA, Banerjee S, Kabir SN. Ovotoxic effects of galactose involve attenuation of follicle-stimulating hormone bioactivity and up-regulation of granulosa cell p53 expression. PLoS One. 2012;7(2):e30709.
155. Calderon FR, Phansalkar AR, Crockett DK, Miller M, Mao R. Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene.HumMutat. 2007;28(10): 939-943.
156. Matthijs G, Schollen E, Pardon E, et al. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet. 1997;16(1):88-92.
157. Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF, Bonfa E. Autoimmune primary ovarian insufficiency. Autoimmun Rev. 2014;13(4-5):427-430.
158. La Marca A, Brozzetti A, Sighinolfi G, Marzotti S, Volpe A, Falorni A. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol. 2010;22(4):277-282.
159. Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction inwomen with 46, XX spontaneous premature ovarian failure. Fertil Steril. 2005;84(4):958-965.
160. Falorni A, Laureti S, Candeloro P, Perrino S, Coronella C, Bizzarro A, Bellastella A, Santeusanio F, De Bellis A. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril. 2002;78(2):270-279.
161. Cervato S, Mariniello B, Lazzarotto F, et al. Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. Clin Endocrinol (Oxf). 2009;70(3):421-428.
162. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol. 2009;161(1):11-20.
163. Conway GS, Payne NN, Webb J, Murray A, Jacobs PA. FragileXpremutation screening in women with premature ovarian failure. Hum Reprod. 1998;13(5):1184-1187.
164. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol. 2012;7:219-245.
165. Schwartz CE, Dean J, Howard-Peebles PN, et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet. 1994;51(4):400-402.
166. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POFin FragileXstudy-preliminary data.AmJMedGenet. 1999;83(4):322-325.
167. Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1repeat size with ovarian dysfunction.HumReprod. 20(2)05;20:402-412.
168. Ennis S, Ward D, Murray A. Nonlinear association betweenCGGrepeat number and age of menopause inFMR1 premutation carriers. Eur J Hum Genet. 2006;14(2):253-255.
169. Murray A, Ennis S, MacSwiney F, Webb J, Morton NE. Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet. 2000;8(4):247-252.
170. Welt CK, Smith PC, Taylor AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab. 2004;89(9):4569-4574.
171. Rohr J, Allen EG, Charen K, et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod. 2008;23(5):1220-1225.
172. Chen E, Joseph S. Fragile X mental retardation protein: a paradigm for translational control by RNA-binding proteins. Biochimie. 2015;114:147-154.
173. Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA. 2002;8(12):1482-1488.
174. Elizur SE, Lebovitz O, Derech-Haim S, et al. Elevated levels ofFMR1mRNAin granulosa cells are associated with low ovarian reserve in FMR1 premutation carriers. PLoS One. 2014;9(8):e105121.
175. Murray A, Webb J, Dennis N, Conway G, Morton N. Microdeletions in FMR2 may be a significant cause of premature ovarian failure. J Med Genet. 1999;36(10):767-770.
176. Hook EB, Warburton D. Turner syndrome revisited: review of new data supports the hypothesis that all viable 45, X cases are cryptic mosaics with a rescue cell line, implying an origin by mitotic loss. Hum Genet. 2014;133(4): 417-424.
177. Zinn AR. TheXchromosome and the ovary. J Soc Gynecol Investig. 2001;8(1 Suppl Proceedings):S34-S36.
178. Zinn AR, Page DC, Fisher EM. Turner syndrome: the case of the missing sex chromosome. Trends Genet. 19(3)93; 9:90-93.
179. Simpson JL, Rajkovic A. Ovarian differentiation and gonadal failure. Am J Med Genet. 1999;89(4):186-200.
180. KraussCM, TurksoyRN, Atkins L, McLaughlin C, Brown LG, Page DC. Familial premature ovarian failure due to an interstitial deletion of the long arm of the X chromosome. N Engl J Med. 1987;317(3):125-131.
181. Burgoyne PS, Baker TG. Perinatal oocyte loss in XO mice and its implications for the aetiology of gonadal dysgenesis in XO women. J Reprod Fertil. 1985;75(2):633-645.
182. Jacobs PA, Baikie AG, Brown WM, Macgregor TN, Maclean N, Harnden DG. Evidence for the existence of the human "super female". Lancet. 1959;2(7100):423-425.
183. Villanueva AL, Rebar RW. Triple-X syndrome and premature ovarian failure. Obstet Gynecol. 1983;62(3 suppl): 70s-73s.
184. Tungphaisal S, Jinorose U. True 47, XXX in a patient with premature ovarian failure: the first reported case in Thailand. J Med Assoc Thai. 1992;75(11):661-665.
185. Jiao X, Qin C, Li J, et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure.HumReprod. 2012;27(7):2201-2207.
186. Goswami R, Goswami D, Kabra M, Gupta N, Dubey S, Dadhwal V. Prevalence of the triple X syndrome in phenotypically normal women with premature ovarian failure and its association with autoimmune thyroid disorders. Fertil Steril. 2003;80(4):1052-1054.
187. Sarto GE, Therman E, Patau K. X inactivation in man: a woman with t(Xq-;12q+).AmJ Hum Genet. 1973;25(3): 262-270.
188. ThermanE, Laxova R, Susman B.The critical region on the human Xq. Hum Genet. 1990;85(5):455-461.
189. Zhu J, Petersen S, Tessarollo L, Nussenzweig A. Targeted disruption of the Nijmegen breakage syndrome gene NBS1 leads to early embryonic lethality in mice. Curr Biol. 2001; 11(2):105-109.
190. Thiel C, Lbke T, Matthijs G, von Figura K, Krner C. Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality. Mol Cell Biol. 2006; 26(15):5615-5620.
191. Keyes LN, Spradling AC. The Drosophila gene fs(2)cup interacts with otu to define a cytoplasmic pathway required for the structure and function of germ-line chromosomes. Development. 1997;124(7):1419-1431.
192. Lawson KA, Dunn NR, Roelen BA, et al. Bmp4 is required for the generation of primordial germ cells in the mouse embryo. Genes Dev. 1999;13(4):424-436.
193. Ying Y, Liu XM, Marble A, Lawson KA, Zhao GQ. Requirement of Bmp8b for the generation of primordial germ cells in the mouse. Mol Endocrinol. 2000;14(7):1053-1063.
194. Ying Y, Zhao GQ. Cooperation of endoderm-derived BMP2and extraembryonic ectoderm-derivedBMP4in primordial germ cell generation in the mouse. Dev Biol. 2001; 232(2):484-492.
195. Kneitz B, Cohen PE, Avdievich E, et al. MutS homolog 4 localization to meiotic chromosomes is required for chromosome pairing during meiosis in male and female mice. Genes Dev. 2000;14(9):1085-1097.
196. de Vries SS, Baart EB, Dekker M, et al. Mouse MutS-like protein Msh5 is required for proper chromosome synapsis in male and female meiosis. Genes Dev. 1999;13(5):523-531.
197. Baudat F, Manova K, Yuen JP, Jasin M, Keeney S. Chromosome synapsis defects and sexually dimorphic meiotic progression in mice lacking Spo11. Mol Cell. 2000;6(5): 989-998.
198. Mandon-Ppin B, Touraine P, Kuttenn F, et al. Genetic investigation of four meiotic genes in women with premature ovarian failure. Eur J Endocrinol. 2008;158(1):107-115.
199. Kuroda H, Terada N, Nakayama H, Matsumoto K, Kitamura Y. Infertility due to growth arrest of ovarian follicles in Sl/Slt mice. Dev Biol. 1988;126(1):71-79.
200. Buehr M, McLaren A, Bartley A, Darling S. Proliferation and migration of primordial germ cells in We/We mouse embryos. Dev Dyn. 1993;198(3):182-189.
201. Smith ER, Yeasky T, Wei JQ, et al. White spotting variant mouse as an experimental model for ovarian aging and menopausal biology. Menopause. 2012;19(5):588-596.
202. Soyal SM, Amleh A, Dean J. FIGβ, a germ cell-specific transcription factor required for ovarian follicle formation. Development. 2000;127(21):4645-4654.
203. Song ZH, Yu HY, Wang P, et al. Germ cell-specific Atg7 knockout results in primary ovarian insufficiency in female mice. Cell Death Dis. 2015;6:e1589.
204. Gazdag E, Santenard A, Ziegler-Birling C, et al. TBP2 is essential for germ cell development by regulating transcription and chromatin condensation in the oocyte. Genes Dev. 2009;23(18):2210-2223.
205. Boyer A, Lapointe E, Zheng X, et al.WNT4is required for normal ovarian follicle development and female fertility. FASEB J. 2010;24(8):3010-3025.
206. Jnen M, Prunskaite-Hyyrylen R, Naillat F, et al. WNT4 is expressed inhumanfetal and adult ovaries and its signaling contributes to ovarian cell survival. Mol Cell Endocrinol. 2010;317(1-2):106-111.
207. Ledent C, Demeestere I, Blum D, et al. Premature ovarian aging in mice deficient for Gpr3. Proc Natl Acad Sci USA. 2005;102(25):8922-8926.
208. Simon AM, Goodenough DA, Li E, Paul DL. Female infertility in mice lacking connexin 37. Nature. 1997; 385(6616):525-529.
209. Carabatsos MJ, Sellitto C, Goodenough DA, Albertini DF. Oocyte-granulosa cell heterologous gap junctions are required for the coordination of nuclear and cytoplasmic meiotic competence. Dev Biol. 2000;226(2):167-179.
210. Linher-Melville K, Li J. The roles of glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor and nerve growth factor during the final stage of folliculogenesis: a focus on oocyte maturation. Reproduction. 2013;145(2):R43-R54.
211. Pangas SA, Li X, Umans L, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol. 2008;28(1):248-257.
212. Li Q, Pangas SA, Jorgez CJ, Graff JM, Weinstein M, Matzuk MM. Redundant roles of SMAD2 and SMAD3 in ovarian granulosa cells in vivo. Mol Cell Biol. 2008; 28(23):7001-7011.
213. Lai D, Wang F, Yao X, Zhang Q, Wu X, Xiang C. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. J Transl Med. 2015;13:155.
214. Dang J, Jin Z, Liu X, Hu D, Wang Z. Human cord blood mononuclear cell transplantation for the treatment of premature ovarian failure in nude mice. Int J Clin Exp Med. 2015;8(3):4122-4127.
215. Kawamura K, Cheng Y, Suzuki N, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad SciUSA. 2013;110(43): 17474-17479.
216. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508(7497):469-476.
217. Fonseca DJ, Ojeda D, Lakhal B, et al. CITED2 mutations potentially cause idiopathic premature ovarian failure. Transl Res. 2012;160(5):384-388.
218. Ojeda D, Lakhal B, Fonseca DJ, et al. Sequence analysis of the CDKN1B gene in patients with premature ovarian failure reveals a novel mutation potentially related to the phenotype. Fertil Steril. 2011;95(8):2658-2660.e1.
219. Wang B, Li L, Ni F, et al. Mutational analysis of SAL-Like 4 (SALL4) in Han Chinese women with premature ovarian failure. Mol Hum Reprod. 2009;15(9):557-562.
220. Pyun JA, Kang H, Lee SK, KimMH, Kwack K. Association between polymorphisms in the protein L-isoaspartate (Daspartate) O-methyltransferase gene and premature ovarian failure. Fertil Steril. 2009;91(4 suppl):1362-1365.
221. Qin Y, Sun M, You L, et al. ESR1, HK3 and BRSK1 gene variants are associated with both age at natural menopause and premature ovarian failure. Orphanet J Rare Dis. 2012; 7:5.
222. Ledig S, Rpke A, Wieacker P. Copy number variants in premature ovarian failure and ovarian dysgenesis. Sex Dev. 2010;4(4-5):225-232.
223. Norling A, Hirschberg AL, Rodriguez-Wallberg KA, Iwarsson E, Wedell A, Barbaro M. Identification of a duplication within the GDF9 gene and novel candidate genes for primary ovarian insufficiency (POI) by a customized high-resolution array comparative genomic hybridization platform. Hum Reprod. 2014;29(8):1818-1827.
224. Shelling AN, Burton KA, Chand AL, et al. Inhibin: a candidate gene for premature ovarian failure. Hum Reprod. 2000;15(12):2644-2649.
225. Chand AL, Harrison CA, Shelling AN. Inhibin and premature ovarian failure. Hum Reprod Update. 2010;16(1): 39-50.
226. Chand AL, Ooi GT, Harrison CA, Shelling AN, Robertson DM. Functional analysis of the human inhibin α subunit variant A257T and its potential role in premature ovarian failure. Hum Reprod. 2007;22(12):3241-3248.
227. Pyun JA, Kim S, Cha DH, Kwack K. Epistasis between polymorphisms in TSHB and ADAMTS16 is associated with premature ovarian failure. Menopause. 2014;21(8): 890-895.
228. Pyun JA, Kim S, Cha DH, Kwack K. Epistasis between IGF2R and ADAMTS19 polymorphisms associates with premature ovarian failure. Hum Reprod. 2013;28(11): 3146-3154.
229. Pitteloud N, Quinton R, Pearce S, et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest. 2007;117(2): 457-463.
230. Varon R, Seemanova E, Chrzanowska K, et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet. 2000;8(11):900-902.
231. Varon R, Vissinga C, Platzer M, et al. Nibrin, a novelDNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 1998;93(3):467-476.
232. Maser RS, Zinkel R, Petrini JH. An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. Nat Genet. 2001;27(4):417-421.
233. Varon R, Dutrannoy V, Weikert G, et al. Mild Nijmegen breakage syndrome phenotype due to alternative splicing. Hum Mol Genet. 2006;15(5):679-689.
234. Salewsky B, Hildebrand G, Rothe S, et al. Directed alternative splicing in Nijmegen breakage syndrome: proof of principle concerning its therapeutical application. Mol Ther. 2016;24(1):117-124.
235. Lespinasse J, Hoffmann P, Lauge A, et al. Chromosomal instability in two siblings with gonad deficiency: case report. Hum Reprod. 2005;20(1):158-162.
236. WarcoinM, Lespinasse J, Despouy G, et al. Fertility defects revealing germline biallelic nonsense NBN mutations. Hum Mutat. 2009;30(3):424-430.
237. Pronk JC, van Kollenburg B, Scheper GC, van der Knaap MS.Vanishing white matter disease: a review with focus on its genetics. Ment RetardDevDisabil Res Rev. 2006;12(2): 123-128.
238. Peter L, Niel F, Catenoix H, et al. Acute neurological deterioration in ovarioleukodystrophy related to EIF2B mutations: pregnancy with oocyte donation is a potentially precipitating factor. Eur J Neurol. 2008;15(1):94-97.
239. Fogli A, Schiffmann R, Bertini E, et al. The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology. 2004;62(9):1509-1517.
240. Fogli A, Gauthier-Barichard F, Schiffmann R, et al. Screening for known mutations in EIF2B genes in a large panel of patients with premature ovarian failure. BMC Womens Health. 2004(1);4:8.
241. Sold G, Caccia S, Robusto M, et al. First independent replication of the involvement of LARS2 in Perrault syndrome by whole-exome sequencing of an Italian family. J Hum Genet. 2016;61(4):295-300.
242. Oftedal BE, Hellesen A, Erichsen MM, et al. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity. 2015;42(6):1185-1196.
243. Foresta C, Ferlin A, Gianaroli L, Dallapiccola B. Guidelines for the appropriate use of genetic tests in infertile couples. Eur J Hum Genet. 2002;10(5):303-312.
244. Grigsby J, Cornish K, Hocking D, et al. The cognitive neuropsychological phenotype of carriers of the FMR1 premutation. J Neurodev Disord. 2014;6(1):28.
245. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A(8):1009-1016.
246. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. 2009; 17(10):1359-1362.
247. Verdin H, De Baere E. FOXL2 impairment in human disease. Horm Res Paediatr. 2012;77(1):2-11.
248. Baxter RM, Arboleda VA, Lee H, et al. Exome sequencing for the diagnosis of 46, XY disorders of sex development. J Clin Endocrinol Metab. 2015;100(2):E333-E344.
249. Ainsworth C. Sex redefined. Nature. 2015;518(7539): 288-291.
250. Roche MI, Berg JS. Incidental findings with genomic testing: implications for genetic counseling practice. Curr Genet Med Rep. 2015;3(4):166-176.
251. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7): 565-574.
252. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med. 2015;17(1): 68-69.
253. Kocarnik JM, Fullerton SM. Returning pleiotropic results from genetic testing to patients and research participants. JAMA. 2014;311(8):795-796.